We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents. Earnings also surpassed the year-ago quarter’s figure of 66 cents.
Quarter Details
DENTSPLY’s net sales increased to $1,009.2 million from $954 million in the year-ago period. The same also beat the Zacks Consensus Estimate of $978 million. Net sales, excluding precious metals, increased 4.3% on a constant-currency basis. Internal growth was 2.4% from the third quarter of 2016.
In the quarter, U.S. sales rose 8.4% to $363.8 million from $335.6 million in the year-ago quarter. Net sales in Europe increased 8.2% to $386.6 million. Net sales in Rest of World declined 1% to $258.8 million.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
Total cash and cash equivalents of the company declined to $370.0 million as of Sep 30, from $383.9 million as of Dec 31, 2016. Cash generated from operations in the first nine months of 2017 was $373 million compared with $341 million in the year-ago period. As of Sep 30, the company’s long-term debt was $1.60 billion versus $1.51 billion at year-end 2016.
Guidance
The company narrowed its adjusted EPS guidance for 2017 in the range of $2.65-$2.70 per share. Earlier, the company projected adjusted EPS in a range of $2.65-$2.75.
Zacks Rank & Key Picks
Currently, DENTSPLY carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported second-quarter fiscal 2018 earnings of 43 cents, up 79.2% from 24 cents in the year-ago quarter. Gross margin expanded 548 bps year over year to 35.2%.
Luminex reported third-quarter 2017 adjusted earnings of 19 cents, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted third-quarter 2017 adjusted earnings of $2.77, up 34.5% on a year-over-year basis. Revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
DENTSPLY SIRONA Inc. (XRAY - Free Report) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents. Earnings also surpassed the year-ago quarter’s figure of 66 cents.
Quarter Details
DENTSPLY’s net sales increased to $1,009.2 million from $954 million in the year-ago period. The same also beat the Zacks Consensus Estimate of $978 million. Net sales, excluding precious metals, increased 4.3% on a constant-currency basis. Internal growth was 2.4% from the third quarter of 2016.
In the quarter, U.S. sales rose 8.4% to $363.8 million from $335.6 million in the year-ago quarter. Net sales in Europe increased 8.2% to $386.6 million. Net sales in Rest of World declined 1% to $258.8 million.
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise
DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise | DENTSPLY SIRONA Inc. Quote
Financial Update
Total cash and cash equivalents of the company declined to $370.0 million as of Sep 30, from $383.9 million as of Dec 31, 2016. Cash generated from operations in the first nine months of 2017 was $373 million compared with $341 million in the year-ago period. As of Sep 30, the company’s long-term debt was $1.60 billion versus $1.51 billion at year-end 2016.
Guidance
The company narrowed its adjusted EPS guidance for 2017 in the range of $2.65-$2.70 per share. Earlier, the company projected adjusted EPS in a range of $2.65-$2.75.
Zacks Rank & Key Picks
Currently, DENTSPLY carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported second-quarter fiscal 2018 earnings of 43 cents, up 79.2% from 24 cents in the year-ago quarter. Gross margin expanded 548 bps year over year to 35.2%.
Luminex reported third-quarter 2017 adjusted earnings of 19 cents, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted third-quarter 2017 adjusted earnings of $2.77, up 34.5% on a year-over-year basis. Revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>